Mitochondrial dysfunction in myasthenia gravis: Exploring directions for future immunotherapy? A review

Area of Science:

• Neurology
• Immunology
• Cell Biology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, causing muscle weakness and fatigue.
• Chronic MG presents challenges due to treatment resistance and relapses, impacting patients significantly.
• Emerging evidence links mitochondrial dysfunction to impaired muscle function and immune responses in MG.

Purpose of the Study:

• To explore mitochondrial function and morphology in MG pathogenesis.
• To investigate mitochondrial quality control and metabolic reprogramming in MG.
• To review current and potential mitochondrial-targeted therapies for MG.

Main Methods:

• Review of literature on mitochondrial dysfunction in MG.
• Analysis of pathological processes involving mitochondria in MG.
• Examination of drug therapies targeting mitochondrial function.

Main Results:

• Mitochondrial dysfunction is implicated in oxidative stress, altered dynamics, mitophagy, and metabolism in MG.
• Abnormal mitochondrial morphology and function are key features in MG.
• Mitochondrial quality control and metabolic reprogramming are critical to MG pathology.

Conclusions:

• Mitochondrial dysfunction plays a crucial role in the pathogenesis of myasthenia gravis.
• Targeting mitochondrial pathways offers promising therapeutic strategies for MG.
• Further research into mitochondrial mechanisms can guide novel MG treatments.